Table 1. Distribution of experimental groups, prenatal exposures, and postnatal pretreatments.
Experiment | Group identification | Numbers of rats |
Prenatal exposure; gestational day |
Postnatal (AED) pretreatment, postnatal day |
Postnatal trigger of spasms, postnatal day |
|
---|---|---|---|---|---|---|
Clustering of spasms (Figure 1) |
P10 | saline | n=7 | saline G15 | none | NMDA P10 |
betamethasone | n=9 | betamethasone G15 | none | NMDA P10 | ||
| ||||||
P15 | saline | n=6 | saline G15 | none | NMDA P15 | |
betamethasone | n=5 | betamethasone G15 | none | NMDA P15 | ||
| ||||||
Repeated trigger of spasms (Figure 2) |
saline | n=7 | saline G15 | none | NMDA P12, P13, P15 | |
betamethasone | n=9 | betamethasone G15 | none | NMDA P12, P13, P15 | ||
| ||||||
Randomized ACTH trial (Figure 3) |
saline | n=11 | betamethasone G15 | saline 2× P12, 3× P13, 3× P14 | NMDA P12, P13, P15 | |
ACTH | n=11 | betamethasone G15 | ACTH 0.3 mg/kg, 2× P12, 3x P13, 3× P14 |
NMDA P12, P13, P15 | ||
| ||||||
Pharmacology of the model (Figure 4) |
saline | n=4 | betamethasone G15 | saline P14 | NMDA P15 | |
GVG 100 | n=7 | betamethasone G15 | vigabatrin 100 mg/kg P14 | NMDA P15 | ||
GVG 250 | n=8 | betamethasone G15 | vigabatrin 250 mg/kg P14 | NMDA P15 | ||
| ||||||
saline | n=16 | betamethasone G15 | saline P15 | NMDA P15 | ||
MPD 5 | n=10 | betamethasone G15 | methylprednisolone 5 mg/kg P15 |
NMDA P15 | ||
MPD 20 | n=8 | betamethasone G15 | methylprednisolone 20 mg/kg P15 |
NMDA P15 | ||
MPD 60 | n=7 | betamethasone G15 | methylprednisolone 60 mg/kg P15 |
NMDA P15 | ||
| ||||||
saline P13-P15 | n=6 | betamethasone G15 | saline P13, P14, P15 | NMDA P15 | ||
MPD P13-P15 | n=9 | betamethasone G15 | methylprednisolone 60 mg/kg P13, P14, P15 |
NMDA P15 | ||
| ||||||
vehicle 24 hours | n=9 | betamethasone G15 | 1% alcohol P14 | NMDA P15 | ||
rapamycin 24 hours | n=10 | betamethasone G15 | rapamycin 3 mg/kg P14 | NMDA P15 | ||
| ||||||
vehicle P7-P14 | n=4 | betamethasone G15 | 1% alcohol daily P7-P14 | NMDA P15 | ||
rapamycin P7-P14 | n=9 | betamethasone G15 | rapamycin 3 mg/kg daily P7 -P14 |
NMDA P15 | ||
| ||||||
Behavioral outcome (Figure 5) |
saline – no spasms | n=11 | betamethasone G15 | none | saline P15 | |
P15 spasms | n=11 | betamethasone G15 | none | NMDA P15 | ||
serial spasms | n=6 | betamethasone G15 | none | NMDA P12, P13, P15 | ||
| ||||||
saline-3×3 | n=9 | betamethasone G15 | saline 3× P12, 3× P13, 3× P14 | NMDA P15 | ||
ACTH-3×3 | n=10 | betamethasone G15 | ACTH 0.3 mg/kg, 3× P12, 3× P13, 3× P14 |
NMDA P15 | ||
| ||||||
saline ×3 | n=4 | betamethasone G15 | saline P13, P14, P15 | NMDA P15 | ||
MPD 60 ×3 | n=3 | betamethasone G15 | methylprednisolone 60 mg/kg P13, P14, P15 |
NMDA P15 |